spleen with 4 weeks of induction therapy. The potent effect of SINE compound monotherapy on GC and auto-reactive ASC was further highlighted by the pronounced elimination of GCs histologically and reduction in auto-reactive ASC achieved after 4 weeks of maintenance therapy administered once weekly. In a concurrent study, when combined with bortezomib, 1 week verdinexor plus PI treatment resulted in a synergetic effect, significantly reducing in the number of auto-reactive ASC, particularly in the BM.

Conclusions Verdinexor has demonstrated efficacy by reducing generation and survival of auto-reactive immune cells. Additional experiments are underway to examine if inhibition of the canonical NFkB pathway underlies verdinexors inhibitory effect. Together, our findings suggest the potential of SINE compounds to have a significant impact on SLE disease progression alone or in combination with currently utilized PIs.

Funding Source(s): NIH R44 AI124949-03

229 CLINICAL CHARACTERISTICS OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH MALIGNANT TUMORS

Honglian Yu. Shuangyi Campus of Ningxia Medical University

Background Rheumatic disease is caused by immune abnormality, which results in the immune response of the body to auto-antigens and causes tissue damage. The immune system eliminates or inhibits the growth of tumor cells through various ways. When the immune function abnormality leads to the escape of immune surveillance of tumor cells, it can lead to tumorigenesis. The risk of malignant tumors is higher than ordinary people in systemic lupus erythematosus (SLE) patients, which were mainly hematological tumors, especially non-Hodgkin lymphoma. The risk of Hodgkin lymphoma, leukemia and multiple myeloma was also increased, which was associated with BAFF changes, APRIL signal transduction, increased IL-6 activity and EB virus infection. Increased risk of malignant tumors in SLE patients, including lung cancer, hepatobiliary cancer, thyroid cancer, vulvar/vaginal malignancies and cervical dysplasia, was also reported, which was associated with SLE disease activity in specific organs, inflammatory stimulation, oxidative damage, changes in viral clearance, and/or specific drug use.

Methods Twenty SLE patients with malignant tumors admitted to the General Hospital of Ningxia Medical University from October 2008 to October 2018 were selected. Their sex, age, time of diagnosis of rheumatism and tumors, types of tumors, clinical stages and prognosis were summarized and analyzed.

Results Malignant tumors occurred in 20 (0.50%) of 3970 SLE patients, the average age was 54.43 ± 7.95. There were 4 cases of lung cancer, 3 cases of non-Hodgkin lymphoma and liver cancer, 2 cases of thyroid cancer, uterine cancer and skin cancer, multiple myeloma, gastric cancer, pancreatic cancer, and nasopharyngeal carcinoma were found in 1 case respectively. The median course of malignant tumors in SLE patients was 3.42 years, 79.41% of the patients were diagnosed before tumors, 16.35% of the cases occurred at the same time, and only 4.24% of tumors were diagnosed before SLE. Phase IV was the most common clinical stage in the diagnosis of tumors, accounting for 59.74%. In SLE patients with tumors, the survival time ranged from 1 month to 39 months, with a median survival time of 9.2 months.

Conclusions Most malignant tumors are found after SLE diagnosis, with a median course of 3.42 years, and occur more frequently between the ages of 50 and 60. SLE may be associated with various types of malignant tumors, Lung cancer, non-Hodgkin’s lymphoma and Liver cancer were the most common tumors, and the clinical staging of tumors is late and the prognosis is poor, with the median survival time is 9.2 months.

Funding Source(s): None

230 SYSTEMIC LUPUS ERYTHEMATOSUS AND RAPIDLY PROGRESSIVE CARDIOGENIC SHOCK

Anam Umar*, Eric Chang, Muhammad Bilal, Cinnamon Bradley. Morehouse School of Medicine

Background Symptomatic lupus myocarditis is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Clinical manifestation is variable and includes dyspnea, chest pain, peripheral edema, fever, nausea, vomiting, or palpitations. We describe a case of a young female who developed rapid progressive cardiogenic shock secondary to lupus myocarditis.

Methods Not applicable as it is a clinical vignette.

The abstract for clinical vignette is attached as a separate document

Results Not applicable as it is a clinical vignette

The abstract for clinical vignette is attached as a separate document

Conclusions The diagnosis of lupus myocarditis is usually achieved clinically and with the use of TTE, cardiac MRI or biopsy. However, none of the current diagnostic modalities have established sensitivity or specificity. Our patient only developed significant TTE findings during the late stage, which led to an unfortunate delay in diagnosis. We suggest that physicians should always have a broad differential diagnosis and high clinical suspicion to avoid late diagnosis and mismanagement of patients, especially when dealing with cardiac manifestations of SLE.

Funding Source(s): None

231 TRNA DERIVED FRAGMENTS(TRFS) REGULATE OXIDATIVE PHOSPHORYLATION TO PARTICIPATE IN SLE PATHOGENESIS

1 Guannan Geng, 2 Huijing Wang*, 3 Shuang Ye. 1 Renji Hospital, South campus, School of Medicine, Shanghai Jiao Tong University; 2 Department of Rheumatology, South Campus, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China; 3 Department of Rheumatology, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Background tRNA derived fragments (tRFs) are 18 to 40-nucleotide(nt) small RNAs cleaved from mature tRNAs or pre-cursor tRNA transcripts. There is growing evidence that tRFs play important roles in cellular homeostasis. This study focused on abnormal expression of tRFs in CD4 +T lymphocytes from SLE patients, their function on
regulation of oxidative metabolism and potential roles in development of systemic lupus erythematosus (SLE).

**Methods** CD4 + T lymphocytes isolated from 97 SLE patients, 30 RA patients, 10 AS patients and 20 healthy donors were used in our *in vitro* experiments. Total RNA of CD4 + T lymphocytes isolated from 4 SLE patients and 3 healthy donors were used to perform small RNA sequencing. Total RNA of CD4 + T lymphocytes transfected with synthetic tRF-3009 or negative control (a random sequence, single strand) were used to perform next generation sequencing. CD4 + T lymphocytes isolated from healthy donors were transfected with tRF-3009/negative control or tRF-3009 siRNA/si-NC in *in vitro*, with/without IFN-alpha treatment, to analyze OCRROS and ATP concentration. Real-time qRT-PCR was performed to analyze expression of tRF-3009 and related gene expressions.

**Results** We have identified a series of tRFs expressed abnormally in SLE CD4 + T lymphocytes. Interestingly, almost all up regulated tRFs were from 3'end of mature tRNA while down regulated ones were from 3'end of tRNA precursors. We have found that expression of tRF-3009 was correlated with lupus nephritis (LN) and urine protein (PRO). The expression of tRF-3009 could be induced by IFN-alpha treatment in *in vitro*. Knockdown of tRF-3009 by siRNA could rescue the metabolism change of CD4 + T lymphocytes induced by IFN-alpha. Transfection of tRF-3009 alone could up regulate oxidative phosphorylation of CD4 + T lymphocytes in *in vitro*.

**Conclusions** This study identified a series of abnormally expressed tRFs existed in CD4 + T lymphocytes isolated from SLE patients. One of these small RNAs, tRF-3009 also enriched in kidney and correlated with occurrence of lupus nephritis. tRF-3009 anticipated in metabolism regulation, may play important roles in SLE pathogenesis.

**Funding Source(s):** The National Key Research and Development Program of China(2016YFC0903900 and 2017YFC0909000)

---

**Abstract 232 Table 1 Results of Binary Logistic Model of Predictors of HCQ Treatment Adherence**

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Odds Ratio</th>
<th>95% Confidence Interval</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black</td>
<td>0.35</td>
<td>0.18–0.67</td>
<td>0.002*</td>
</tr>
<tr>
<td>Other (mixed, American Indian/Alaskan Native,</td>
<td>0.35</td>
<td>0.14–0.85</td>
<td>0.021*</td>
</tr>
<tr>
<td>Pacific Islander, or Middle Eastern)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate severity of lupus at diagnosis</td>
<td>0.57</td>
<td>0.31–1.03</td>
<td>0.061</td>
</tr>
<tr>
<td>HCQ improves/helps treat my symptoms</td>
<td>2.49</td>
<td>1.25–4.92</td>
<td>0.009*</td>
</tr>
<tr>
<td>Positive impression of HCQ</td>
<td>2.14</td>
<td>1.08–4.24</td>
<td>0.029*</td>
</tr>
<tr>
<td>Rheumatologist as primary doctor treating lupus</td>
<td>2.0</td>
<td>1.01–3.95</td>
<td>0.046*</td>
</tr>
</tbody>
</table>

*Significant p-value<0.05.

Next, 13 variables with a p-value<0.20 were entered into a binary logistic model using backwards stepwise selection.

**Results** 2028 individuals reported currently taking HCQ with 1581 (78.0%) individuals reporting taking the medication exactly as prescribed all of the time, 385 (19.0%) reporting some of the time, and 62 (3.1%) reporting sometimes or never taking HCQ as prescribed. People with lupus were twice as likely to adhere to HCQ if they reported having a rheumatologist as the primary doctor treating their lupus (p=0.046, OR=2.00) and more than twice as likely if they reported having a positive impression of HCQ (p=0.029, OR=2.14) or experienced improvement in treating their symptoms using HCQ (p<0.009, OR=2.49). Notably, African Americans and those indicating race as Other (mixed, American Indian/Alaskan Native, Pacific Islander or Middle Eastern) were 65% less likely to adhere to HCQ treatment (p=0.002, OR=0.35; p=0.021, OR=0.35, respectively).

**Conclusions** The study confirms the importance of experiential factors such as medication impression and patient-reported symptom improvement in HCQ treatment adherence. Additionally, results highlight the potential significance of having a specialist as the primary lupus doctor. This may be due to rheumatologists higher awareness of the value of HCQ for lupus patients compared to other providers. Further exploration is needed on cultural factors negatively influencing treatment adherence among certain racial groups, particularly African Americans and Other racial groups (mixed, American Indian/Alaskan Native, Pacific Islander or Middle Eastern). Treatment adherence is particularly important in lupus given the complex nature of the disease and fluctuation of disease activity, which may be exacerbated by poor adherence.

**Funding Source(s):** UCB Pharma funded study data collection.

---

**Abstract 233 AUTOANTIBODY-POSITIVE HEALTHY INDIVIDUALS CONSTRAINT T CELL PATHWAYS TO REGULATE AUTOIMMUNE DISEASE**

1Samantha Sligh-Webb, 1Aleksandra Bilynska, 1Miles Smith, 1Rufei Lu, 1Hua Chen, 1Krista Bean, 1Melissa Munroe, 1Holden Maeker, 1Paul J Utz, 1Joan T Merrill, 2Eliza Chakravarty, 1Cristina Ariens, 1Joel Guthridge, 1Judith A James*. 1University of Oklahoma, 2Stanford University, 3Oklahoma Medical Research Foundation; 4Stanford University; 5Oklahoma Medical Research Foundation: University of Oklahoma

10.1136/lupus-2019-lsm.233

**Background** Anti-nuclear antibody (ANA) positivity is a principal feature of individuals with an autoimmune disease, yet up to one in five healthy individuals are ANA-positive (ANA+).